KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Quest Diagnostics (DGX) EBT (2016 - 2025)

Quest Diagnostics' EBT history spans 17 years, with the latest figure at $330.0 million for Q4 2025.

  • For Q4 2025, EBT rose 10.37% year-over-year to $330.0 million; the TTM value through Dec 2025 reached $1.3 billion, up 12.17%, while the annual FY2025 figure was $1.3 billion, 12.17% up from the prior year.
  • EBT for Q4 2025 was $330.0 million at Quest Diagnostics, up from $328.0 million in the prior quarter.
  • Across five years, EBT topped out at $817.0 million in Q2 2021 and bottomed at $109.0 million in Q4 2022.
  • The 5-year median for EBT is $320.0 million (2022), against an average of $372.8 million.
  • The largest annual shift saw EBT surged 430.51% in 2021 before it tumbled 78.29% in 2022.
  • A 5-year view of EBT shows it stood at $502.0 million in 2021, then crashed by 78.29% to $109.0 million in 2022, then surged by 117.43% to $237.0 million in 2023, then grew by 26.16% to $299.0 million in 2024, then rose by 10.37% to $330.0 million in 2025.
  • Per Business Quant, the three most recent readings for DGX's EBT are $330.0 million (Q4 2025), $328.0 million (Q3 2025), and $384.0 million (Q2 2025).